ARKG Holdings — ARK Genomic Revolution ETF
All 33 reported holdings of ARK Genomic Revolution ETF (ARKG) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Tempus Ai, Inc. | 9.42% | $116.42M |
| Twist Bioscience Corp. | 8.99% | $111.09M |
| Crispr Therapeutics AG | 8.91% | $110.11M |
| 10x Genomics, Inc. | 5.77% | $71.28M |
| Beam Therapeutics, Inc. | 5.43% | $67.09M |
| Absci Corp. | 4.78% | $59.08M |
| Natera, Inc. | 4.07% | $50.24M |
| Illumina, Inc. | 4.03% | $49.79M |
| Intellia Therapeutics, Inc. | 3.82% | $47.16M |
| Personalis, Inc. | 3.58% | $44.26M |
| Recursion Pharmaceuticals, Inc. | 3.51% | $43.42M |
| Guardant Health, Inc. | 3.49% | $43.19M |
| Caredx, Inc. | 3.38% | $41.82M |
| Veracyte, Inc. | 2.66% | $32.92M |
| Compass Pathways PLC | 2.43% | $30.04M |
| Adaptive Biotechnologies Corp. | 2.42% | $29.94M |
| Nurix Therapeutics, Inc. | 2.33% | $28.79M |
| Genedx Holdings Corp. | 2.04% | $25.24M |
| Schrodinger, Inc. | 2.03% | $25.03M |
| Arcturus Therapeutics Holdings, Inc. | 1.96% | $24.21M |
| Butterfly Network, Inc. | 1.89% | $23.42M |
| Ionis Pharmaceuticals, Inc. | 1.74% | $21.55M |
| Ataibeckley, Inc. | 1.48% | $18.23M |
| Prime Medicine, Inc. | 1.41% | $17.46M |
| Pacific Biosciences Of California, Inc. | 1.41% | $17.43M |
| Cerus Corp. | 1.22% | $15.12M |
| Alamar Biosciences, Inc. | 1.21% | $14.94M |
| 908 Devices, Inc. | 1.08% | $13.34M |
| Biontech SE | 1.06% | $13.13M |
| Eli Lilly & Company | 0.95% | $11.75M |
| Quantum-Si, Inc. | 0.55% | $6.79M |
| Generate Biomedicines, Inc. | 0.51% | $6.36M |
| Goldman Sachs Financial Square Treasury Obligations Fund | 0.13% | $1.58M |
ARKG overview: performance, fees, allocation and SEC filings